Receptor Partners

MycroDose Therapeutics is a U.S.-based pharmaceutical company focused on developing advanced drug delivery systems that utilize psychedelic compounds for the treatment of mental health disorders and cognitive degenerative diseases. The company is actively working on two of its four core technologies, which include a psilocybin transdermal delivery system and a ketamine oral mucosa delivery system. By leveraging these innovative approaches, MycroDose Therapeutics aims to enhance the efficacy and accessibility of treatments for patients dealing with these challenging conditions.

Mindstate Design Labs is a clinical-stage biotechnology company focused on developing innovative psychedelic-inspired therapeutics aimed at addressing intractable mental health and behavioral conditions. The company employs a unique platform that combines natural history and computational methods to map the biological basis of various psychedelic experiences. This mapping allows Mindstate Design Labs to design psychoactive effects intended for use in medically supervised environments, targeting the root causes of mental health disorders. By utilizing serotonergic agonists, the company seeks to enable healthcare institutions to effectively alter states of consciousness for therapeutic purposes.

Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases and mental health disorders. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic psilocybin derivative aimed at treating frontotemporal dementia (FTD). Psilera's approach involves repurposing psychoactive natural products to develop next-generation therapies that enhance cognitive function and address mood and substance use disorders. Committed to scientific excellence, Psilera aims to transform the lives of individuals affected by these challenging conditions through its pioneering research and development efforts.